当前位置: 首页 > 详情页

MicroRNA-21 Expression is regulated by ss-catenin/STAT3 Pathway and Promotes Glioma Cell Invasion by Direct Targeting RECK

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Tianjin Med Univ, Gen Hosp, Dept Neurosurg,Minist Educ,Tianjin Key Lab Injuri, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin, Peoples R China; [2]Capital Med Univ, Beijing Tiantan Hosp, Glioma Ctr, Dept Neurosurg, Beijing, Peoples R China; [3]Tianjin Med Univ, Canc Inst & Hosp, Dept Head & Neck Canc 1, Tianjin, Peoples R China; [4]Tianjin Huan Hu Hosp, Dept Radiat Oncol, Tianjin, Peoples R China; [5]Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA; [6]Tianjin Neurol Inst, Lab Neuro Oncol, 154 Anshan Rd, Tianjin 300052, Peoples R China
出处:
ISSN:

关键词: ss-catenin STAT3 pathway Glioma Invasion MicroRNA-21 (miR-21) Transcriptional regulation

摘要:
Aims MicroRNA-21 (miR-21) expression is increased in many types of human malignancy, including glioma. Recent studies report that miR-21 regulates cell invasion by targeting RECK, however, the underlying transcriptional regulation of miR-21 in glioma cells remains elusive. Results Here, we identify a positive correlation between miR-21 expression and pathological grade in glioma tissues. We demonstrate that beta-catenin pathway regulates miR-21 expression in human umbilical vein endothelial cell and glioma cells, and that this regulation is signal transducer and activator of transcription 3 (STAT3)-dependent. Further, chromatin immunoprecipitation and luciferase reporter analysis demonstrate that miR-21 is controlled by an upstream promoter containing a conserved STAT3 binding site. Notably, knockdown of miR-21-inhibited cell invasion by increasing RECK expression and decreased tumor growth in a xenograft model. Conclusion These data provide compelling evidence that beta-catenin regulation of miR-21 via STAT3 plays a role in glioma cell invasion and proliferation and indicate that STAT3 is a potential therapeutic target for glioma intervention.

语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2011]版:
大类 | 3 区 医学
小类 | 3 区 神经科学 3 区 药学
最新[2023]版:
大类 | 1 区 医学
小类 | 2 区 神经科学 2 区 药学
JCR分区:
出版当年[2010]版:
Q1 PHARMACOLOGY & PHARMACY Q2 NEUROSCIENCES
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY Q1 NEUROSCIENCES

影响因子: 最新[2023版] 最新五年平均 出版当年[2010版] 出版当年五年平均 出版前一年[2009版] 出版后一年[2011版]

第一作者:
第一作者机构: [1]Tianjin Med Univ, Gen Hosp, Dept Neurosurg,Minist Educ,Tianjin Key Lab Injuri, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin, Peoples R China;
通讯作者:
通讯机构: [1]Tianjin Med Univ, Gen Hosp, Dept Neurosurg,Minist Educ,Tianjin Key Lab Injuri, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin, Peoples R China; [6]Tianjin Neurol Inst, Lab Neuro Oncol, 154 Anshan Rd, Tianjin 300052, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院